Company intelligence / Profile preview
Incospharm Corporation
South Koreaincospharm.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Incospharm develops novel bioactive peptides targeting cellular autophagy to address a range of skin conditions and metabolic diseases. Its proprietary AMPed™ platform has yielded both marketed cosmetic actives with anti-wrinkle, moisturizing, antioxidant, brightening properties as well as a pipeline of preclinical candidates for chronic dermatological conditions like atopic dermatitis and psoriasis. The company collaborates with industry partners globally.
- Therapeutic areas
- Metabolic DisordersOncologyOtherDermatologyNeurology
- Modalities
- Peptides (autophagy-inducing peptides)Bioactive ingredients from natural product screening
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Arysta Health & Nutrition Sciences (Tokyo) – global sales & marketing partner since foundation
Beyond the preview
Go deeper on Incospharm Corporation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Incospharm Corporation.